The U.S. Food and Drug Administration today announced that it is updating the warning labels required on three gadolinium-based MRI contrast agents sold in the U.S. due to the risk of nephrogenic systemic fibrosis.
FDA updates warning labels on gadolinium contrast
Sep 8, 2010
Latest in MRI
Bruker secures MRI magnet supply agreements worth $500M
January 9, 2026
Siemens Healthineers gets FDA nod for Magnetom Flow
January 8, 2026
LLMs help automate PI-RADS classification from MRI reports
January 5, 2026
















